全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Stability Indicating Simultaneous Validation of Telmisartan and Cilnidipine with Forced Degradation Behavior Study by RP-HPLC in Tablet Dosage Form

DOI: 10.1155/2013/461461

Full-Text   Cite this paper   Add to My Lib

Abstract:

A simple, precise, and accurate RP-HPLC method has been developed and validated for the simultaneous assay of Telmisartan and Cilnidipine in tablets. Isocratic RP-HPLC method was developed on Waters C18 ?mm, 5?μm column using mobile phase as acetonitrile (ACN): buffer pH 3.0 with orthophosphoric acid (68?:?32) at a flow rate of 1.0?mL/min and the detection was carried out at 245?nm using photodiode array detector. Forced degradation study was carried out by oxidation, hydrolysis, photolysis, and heating the drug. The method was validated for specificity, linearity, precision, accuracy, robustness, and solution stability. The method was found to be linear in the concentration range of 40–160?μg/mL with correlation coefficient of 0.9990 for Telmisartan and 10–40?μg/mL with correlation coefficient of 0.9989 for Cilnidipine. Degradation products produced as a result of stress studies did not interfere with the detection of agomelatine; therefore, the assay can be considered to be stability indicating. 1. Introduction Telmisartan is chemically nominated as 4′-[(1,4′-dimethyl-2′-propyl[2,6′-bi-1H-benzimidazole]-1′-yl) methyl] [1,1′-biphenyl]-2-carboxylic acid (Figure 1). Its molecular formula is C33H30N4O2 and molecular weight is 514.62. It is a diabetes angiotensin receptor blocker that shows high affinity for the angiotensin II type 1 (AT1) receptors, has a long duration of action, and has the longest half-life of any angiotensin II receptor blocker (ARB) [1]. In clinical studies, Telmisartan shows comparable antihypertensive activity to other major antihypertensive classes, such as angiotensin converting enzyme (ACE) inhibitors, beta-blockers, and calcium antagonists [2]. Figure 1: Chemical structure of Telmisartan. Cilnidipine is chemically nominated as 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine carboxylic acid 2-methoxyethyl(2E)-3-phenyl-propenyl ester (Figure 2). It is a dual blocker of L-type voltage-gated calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals that supply blood vessels [3]. Figure 2: Chemical structure of Cilnidipine. The parent drug stability test guideline Q1A (R2) issued by the International Conference on Harmonization (ICH) suggests that stress testing is an essential part of development strategy and is carried out under more serve condition than accelerated conditions. These studies provide information to establish its inherent stability characteristics, leading to identification of degradation products and hence supporting the suitability of the proposed analytical

References

[1]  M. Rama Mohana Reddy, A. Praveen Kumar, V. Krishna Reddy, and S. Wasimul Haque, “Stability-indicating hplc method for simultaneous estimation of low level impurities of telmisartan and hydrochlorothiazide in tablet dosage forms,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 1, pp. 497–504, 2012.
[2]  A. Gupta, R. M. Charde, and M. S. Charde, “Determination of telmisartan and forced degradation behavior by RP-HPLC in tablet dosage form,” International Journal of Pharmaceutical Chemistry, vol. 2, no. 3, pp. 93–99, 2012.
[3]  M. S. Mohammed, “Spctrophotometric method for the estimation of cilnidipine in bulk and pharmaceutical dosage forms,” Oriental Journal of Chemistry, vol. 29, no. 1, pp. 131–134, 2013.
[4]  A. S. Rathore, L. Sathiyanarayanan, and K. R. Mahadik, “Stability-indicating high-performance thin-layer chromatographic method for quantitative estimation of emtricitabine in bulk drug and pharmaceutical dosage form,” ISRN Chromatography, vol. 2012, Article ID 278583, 7 pages, 2012.
[5]  P. P. Vekariya and H. S. Joshi, “Development and validation of RP-HPLC method for azilsartan medoxomil potassium quantitation in human plasma by solid phase extraction procedure,” ISRN Spectroscopy, vol. 2013, Article ID 572170, 6 pages, 2013.
[6]  S. Singh, B. Singh, R. Bahuguna, L. Wadhwa, and R. Saxena, “Stress degradation studies on ezetimibe and development of a validated stability-indicating HPLC assay,” Journal of Pharmaceutical and Biomedical Analysis, vol. 41, no. 3, pp. 1037–1040, 2006.
[7]  M. Bakshi and S. Singh, “Development of validated stability-indicating assay methods—critical review,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 6, pp. 1011–1040, 2002.
[8]  C. D. Niranjan, S. M. Patil, J. K. Sabaji, and A. N. Chivate, “Development of UV spectrophotometric method for estimation and validation of telmisartan as a pure API,” Journal of Pharmacy Research, vol. 5, no. 6, pp. 3331–3333, 2012.
[9]  K. K. Pradhan, U. S. Mishra, A. Sahoo, K. C. Sahu, D. Mishra, and R. Dash, “Method development and validation of Telmisartan in bulk and pharmaceutical dosage forms by UV Spectrophotometric method,” International Journal of Research in Pharmaceutical Sciences, vol. 2, no. 4, pp. 526–530, 2011.
[10]  G. Mahathi, Y. Ravindra Reddy, and P. Uttam Prasad, “Development and validation of telmisartan and atorvastatin calcium in combined dosage form by RP-HPLC,” International Journal of Pharmacy and Technology, vol. 3, no. 3, pp. 3370–3389, 2011.
[11]  A. M. Raja, N. Spoorthy, D. Banji, K. N. V. Rao, C. Vanita, and S. D. Kumar, “Simultaneous estimaton of metroprolol succinate and telmisartan in tablet dosage form by RP-HPLC,” Journal of Pharmacy Research, vol. 5, no. 8, pp. 4585–4587, 2012.
[12]  P. Vani and S. K. Kalyana, “A rapid stability-indicating simultaneous determenation of hydrochlorothiazide, ramipril and telmisartan in combined dosage form by ultra performance liquid chromatography,” Pharmacia Letter, vol. 5, no. 3, pp. 81–89, 2013.
[13]  K. E. Parmar, R. S. Mehta, N. D. Patel, and K. E. Parmar, “Development and validation of HPTLC method for simultaneous determination of telmisartan and chlorthalidone in bulk and pharmaceutical dosage form,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 5, no. 2, pp. 420–425, 2013.
[14]  H. S. Karmalkar, V. V. Vaidya, N. A. Gomes, M. P. Choukekar, and M. B. Kekare, “Determination of cilnidipine from pharmaceutical formulation by high performance thin layer chromatographic method,” Analytical Chemistry, vol. 7, no. 8, pp. 573–576, 2008.
[15]  K.-R. Lee, Y.-J. Chae, J.-H. Lee et al., “Quantification of cilnidipine in human plasma by liquid chromatography-mass spectrometry,” Journal of Liquid Chromatography and Related Technologies, vol. 35, no. 2, pp. 308–320, 2012.
[16]  P. P. Chaudhari and A. V. Bhalerao, “Method validation for spectrophotometric estimation of cilnidipine,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 5, pp. 96–98, 2012.
[17]  P. Pawar, S. V. Gandhi, P. B. Deshpande, B. Padmanabh, S. Vanjari, and S. U. Shelar, “Simultaneous RP-HPLC estimation of cilnidipine and telmisartan in combined table dosage form,” Chemica Sinica, vol. 4, no. 2, pp. 6–10, 2013.
[18]  P. Pawar, P. B. Deshpande, S. Gandhi, and V. Bhavnani, “High performance hin layer chromatographic determenation of cilnidipine and telmisartan in combined dosage form,” International Research Journal of Pharmacy, vol. 3, no. 6, pp. 219–222, 2012.
[19]  G. J. Kher, V. R. Ram, K. L. Dubal, A. H. Bapodara, and H. S. Joshi, “Validation of a stability-indicating LC method for assay of leflunomide in tablets and for determination of content uniformity,” International Journal of ChemTech Research, vol. 3, no. 2, pp. 523–530, 2011.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133